Onabotulinumtoxin A versus Anti-CGRP Antibody Therapy for Chronic Migraine Management
This poster is part of a Virtual Poster Session, hosted by the Ochsner Continuing Medical Education. We encourage you to ask questions and engage in discussion on this poster! Authors will respond to comments between May 25- June 5, 2020.
Presenters
Roshina Khan, MD, Mike Pepper, MD, Elham Azizi, MD, Jose Posas, MD*, Yashar Eshraghi, MD*.
*Senior authors
Poster
(Click here to access this presentation as a PDF.)
Very difficult to blind the study here where the administration technique is so different.
I wonder if that makes a difference here.
You would have to have saline placebo injected either way ontop of the active drug to single-blind it
Interesting and clinically relevant. Was there any difference in pain scores in this population between the different MAB?
Interesting and clinically relevant. Was/could a sub analysis be performed to compare the different MAB?
Great idea. We haven’t done it but it would be an interesting result to see
It will be interesting to see data comparing the efficacy between the members of the Anti-CGRP Class themselves. The onset of pain relief with this class certainly seems clinically significant for patient outcomes.
Interesting! It says 92 vs 116 days is the median time from initiation and 2nd visit, why the difference in the two groups. I agree this tests only one of the CGRP antagonists. Was there a different side effect profile between the groups?
We didn’t measure this outcome but definitely an important variable to explore